Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-09-14

Clinical Trial Update: Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum [Phase 2]

View source ↗

Summary

A Phase 2 exploratory trial of IFX-1 in patients with pyoderma gangrenosum has completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IFX-1 (vilobelimab)

Snippet

Sponsor: InflaRx GmbH | Conditions: Pyoderma Gangrenosum | Phase 2 | Status: COMPLETED | Results posted: 2023-09-14